Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

STATUS

Recruiting
participants needed

20
sponsor

Fujian Medical University

Send

Updated on 19 February 2024

See if I qualify

stem cell transplantation

cell transplantation

azacitidine

myelodysplastic syndromes

allogeneic hematopoietic stem cell transplant

raeb

myelodysplastic syndrome

cag protocol

Summary

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

Details

Condition	MDS-EB
Age	65years or below
Treatment	Azacitidine, CAG Protocol
Clinical Study Identifier	NCT04216355
Sponsor	Fujian Medical University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	New Diagnosed advanced myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant is planned
	Recipient of an allogeneic hematopoietic stem cell transplantation
	Age < 65 years
	ECOG performance status 2
	Written informed consent
	No psychological, familial, social, or geographic reason that would compromise clinical follow up
Exclusion Criteria
	Relapsed or refractory advanced MDS
	Severe pshyciatric or organic disorder, supposed to be independent from advanced MDS, that would contraindicate treatment
	Known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any of the test compounds, materials
	Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk
	A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stem cell transplantation

cell transplantation

azacitidine

myelodysplastic syndromes

allogeneic hematopoietic stem cell transplant

raeb

myelodysplastic syndrome

cag protocol

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT